Aquestive Therapeutics
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.sympazan.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Aquestive Therapeutics
Assertio Holdings, Inc. offers SYMPAZAN, a unique oral film formulation of clobazam used to treat seizures associated with Lennox-Gastaut Syndrome in patients aged 2 years and older. The product is designed for both patients and healthcare professionals, providing resources, prescribing information, and safety guidelines. SYMPAZAN's innovative delivery method allows it to dissolve on the tongue, enhancing patient compliance. The company emphasizes safety information related to the drug's use, including risks of dependence and adverse reactions.Explore more
Popular SearchesAquestive Therapeutics IncSympazanOtter Pharmaceuticals LLCSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aquestive Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Aquestive Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Aquestive Therapeutics recently announced quarterly report
Check out if Aquestive Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Aquestive Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Aquestive Therapeutics has new funding data
Click to see if Aquestive Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Aquestive Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Aquestive Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Aquestive Therapeutics
Compare insights from companies similar to Aquestive Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Aquestive Therapeutics
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Aquestive Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aquestive Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aquestive Therapeutics.
Aquestive Therapeutics Tech Stack
A closer look at the technologies used by Aquestive Therapeutics
Aquestive Therapeutics News & Media
Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association
LAKE FOREST, Ill., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs, today announced that the company will present new data for SYMPAZAN (clobazam) Oral Film in a poster presentation at the 150th Annual Meeting of the American Neurological Association (ANA2025), September 13-16, 2025, Baltimore Marriott WaAssertio Holdings, Inc. Announces FDA Orange Book Listing for New Sympazan® Oral Film Patent
Extends Intellectual Property Protections to 2039 Extends Intellectual Property Protections to 2039Assertio Holdings, Inc. Signs Exclusive License for Sympazan® (clobazam) Oral Film from Aquestive Therapeutics, Inc.
Trailing 12 Month Revenues of Sympazan Were $9.5 Million Assertio Paid $9.0 Million Upfront, Additional $6.0 Million upon Patent Allowance
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aquestive Therapeutics
Sign Up For FreeTo access detailed company insights
Assertio Holdings, Inc. offers SYMPAZAN, a unique oral film formulation of clobazam used to treat seizures associated with Lennox-Gastaut Syndrome in patients aged 2 years and older. The product is designed for both patients and healthcare professionals, providing resources, prescribing information, and safety guidelines. SYMPAZAN's innovative deli... Read More
